Drug intelligence / Profile preview

butalbital + acetaminophen

Development stage
Unknown
Lead developer
Senores Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

Butalbital + acetaminophen is a combination analgesic product developed by Senores Pharmaceuticals for the treatment of tension headaches and migraines. The formulation consists of two active ingredients: butalbital, a barbiturate that acts as a central nervous system (CNS) depressant to relieve tension and promote muscle relaxation, and acetaminophen (paracetamol), a non-aspirin analgesic and antipyretic that provides pain relief and fever reduction. This small molecule combination is available as an oral tablet in multiple strengths, including 50 mg/300 mg, 25 mg/325 mg, and 50 mg/325 mg. It is approved as a generic alternative to branded products like Phrenilin and is indicated for the symptomatic relief of the symptom complex of tension (or muscle contraction) headaches.

Brand names
Phrenilin
Other names
Butalbital and Acetaminophen Tablets USPButalbital/AcetaminophenButalbital/APAP
02

Targets

Nicotinic Acetylcholine ReceptorAMPAR (AMPA receptor)GABRR (GABA-A receptor subunit rho)ADOR (Adenosine receptors)COX

Beyond the preview

Go deeper on butalbital + acetaminophen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on butalbital + acetaminophen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call